Conference on Managing Partnerships with CROs - 5th October 2009

Outsourcing drug development can be an effective way of establishing a product’s true potential, but the information gap formed between a pharmaceutical company and a CRO after a project is outsourced can cause serious problems. Many factors need to be considered before and after a project has been passed over and partners must stay well connected if their relationship is to be a fruitful one.

CRO partnership conferences often focus on establishing a forum for networking and negotiation, but SMi’s Managing Partnerships with CROs event brought a unique perspective on how to proceed after the contract has been signed. Attend ees gained valuable insights into a range of topics from industry experts and explored the potential benefits of new strategies for their own organisations.

Director of Euprotec Limited, Peter Warn, was in attendance to hear keynote addresses from:

• Rikke Winther, Head of Outsourcing Management, H. Lundbeck, and
  
• Michael Herschel, Director, Clinical Research, GlaxoSmithKline